Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.70 +6.96 (+0.13%) Dow
38,884.26 +31.99 (+0.08%) Nasdaq
16,332.56 -16.69 (-0.10%) Bitcoin USD
62,417.93 -1,599.11 (-2.50%) CMC Crypto 200
1,325.19 +30.52 (+2.36%)
Alpine Immune Sciences, Inc. (ALPN)
After hours:
| Previous close | 64.60 |
| Open | 64.60 |
| Bid | 46.49 x 200 |
| Ask | 82.71 x 200 |
| Day's range | 64.57 - 64.67 |
| 52-week range | 7.55 - 64.72 |
| Volume | |
| Avg. volume | 2,312,013 |
| Market cap | 4.238B |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
SEATTLE, April 10, 2024--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
- Business Wire
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Director
- Business Wire
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
SEATTLE, April 01, 2024--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, has announced that the Company will present updated clinical data for povetacicept from RUBY-3, a phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, in a late breaking poster presentation at the World Congress of Nephrology April 13-16, 2024 in Buenos A
